Effect of Etanercept BS1 on Functional Ability, Disease Activity and Health-Related Quality of Life in Elderly Japanese Patients with Rheumatoid Arthritis

Abstract

Aim: To evaluate the effect of the etanercept biosimilar Etanercept BS1 on the functional ability, disease activity and health-related quality of life（HR-QOL）in elderly patients with rheumatoid arthritis（RA）in Japan. Methods: Patients with RA aged 65 years and older participating in a seven-center Japanese prospective cohort study were enrolled（HAPPINESS）. Data were collected at baseline and at 26 and 52 weeks after treatment initiation with Etanercept BS1. Changes in the Geriatric Locomotive Function Scale 25（GLFS-25）score, Disease Activity Score（DAS28-CRP）, Simplified Disease Activity Index（SDAI）, and EuroQol 5 Dimensions 5 Level（EQ-5D-5L）were evaluated throughout the study period. Results: Forty-three patients were followed-up until week 52. The mean age of the patients was 74.2 years. The mean duration of RA was 6.9 years. Thirty-one patients（72.1%）were females. A significant improvement in the GLFS-25 score was confirmed at weeks 26 and 52 compared with the baseline（15.42, 17.60, and 26.37, respectively）. DAS28-CRP（3.72, 2.01, and 2.16, respectively）and SDAI（17.27, 5.18, and 6.08, respectively）improved significantly throughout the study period, as did the EQ-5D-5L scores（0.70, 0.83, and 0.83, respectively）. Conclusion: Etanercept BS1 significantly improved functional ability, disease activity, and HR-QOL in elderly patients with RA.